HealthQuill Amgen
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug Administration.
Drugs Health Pharma

US drug regulator clears Amgen’s biosimilar to treat rare blood disorder

The US drug regulator has approved Amen’s biosimilar, Bkemv,  to treat rare blood disorders, according to a statement from the Food and Drug.

Read More
The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages of small cell lung cancer (ES-SCLC) with disease progression on or after chemotherapy.
Drugs Health Pharma

USFDA gives nod to Amgen’s therapy for treating small cell lung cancer 

HQ Team May 17, 2024: The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages.

Read More
Amgen acquisition
Drugs Pharma

Amgen to buy Dublin-based Horizon for $27.8 billion

Amgen Inc, one of the world's largest biotechnology companies, will acquire Dublin-based Horizon Therapeutics Plc for $27.8 billion.

Read More
X